Innate Pharma
IPHA
11 hedge funds and large institutions have $1.49M invested in Innate Pharma in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 3 closing their positions.
0.68% less ownership
Funds ownership: 1.18% → 0.5% (-0.68%)
8% less funds holding
Funds holding: 12 → 11 (-1)
21% less capital invested
Capital invested by funds: $1.89M → $1.49M (-$398K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$130K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$30.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.73K |
| 4 |
Barclays
London,
United Kingdom
|
+$659 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$965K |
| 2 |
Optiver Holding
Amsterdam,
Netherlands
|
-$182K |
| 3 |
Two Sigma Investments
New York
|
-$38K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$32K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$20.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Bank of America
Charlotte,
North Carolina
| $581K | -$20.5K | -8,987 | -5% |
|
|
2
Optiver Holding
Amsterdam,
Netherlands
| $394K | -$182K | -79,776 | -43% |
|
|
3
Millennium Management
New York
| $267K | +$130K | +57,050 | +390% |
|
4
Morgan Stanley
New York
| $184K | -$17.1K | -7,485 | -13% |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $49.7K | +$30.3K | +13,315 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $11K | +$6.73K | +2,954 | New |
|
|
SPIA
7
Steward Partners Investment Advisory
New York
| $1.86K | – | – | – |
|
|
8
Barclays
London,
United Kingdom
| $1.54K | +$659 | +289 | +235% |
|
9
UBS Group
Zurich,
Switzerland
| $545 | -$9.93K | -4,359 | -97% |
|
10
Citigroup
New York
| $201 | – | – | – |
|
|
11
BlackRock
New York
| – | -$965K | -482,645 | Closed |
|
|
12
Two Sigma Investments
New York
| – | -$38K | -18,789 | Closed |
|
|
13
Balyasny Asset Management
Chicago,
Illinois
| – | -$32K | -16,094 | Closed |
|
14
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$118 | -52 | -29% |
|
IPHA Hedge Fund Activity: Q4 2022 in Review
11 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q4 2022, worth a combined $1.49M — down 21% from $1.89M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of IPHA and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 2 added.
The largest buyer was Millennium Management, adding an estimated $130K. The largest seller was BlackRock, exiting entirely with an estimated $965K sold.
- 11 institutional investors held Innate Pharma (IPHA) as of Q4 2022, down from 12 in Q3 2022.
- Funds reported $1.49M of Innate Pharma stock for Q4 2022, down 21% quarter-over-quarter.
- 2 funds opened new Innate Pharma positions in Q4 2022 and 3 closed out, a net change of -1 holder.
- The largest Innate Pharma buyer in Q4 2022 was Millennium Management, an estimated $130K added.
- The largest Innate Pharma seller in Q4 2022 was BlackRock, an estimated $965K sold.
Based on aggregated 13F filings for Q4 2022.